Individual Coaching With Dr. Israel Barken

Dr. Israel Barken is a prostate cancer specialist who devotes his time to prostate cancer education and research at the Prostate Cancer Research and Education Foundation in San Diego.  However, he is available for one-one-one Coaching.

Dr. Barken can meet with you in person or simply speak with you by telephone to answer questions, provide unbiased insights and guidance about your prostate cancer.   Web Meetings or Skype calls can also be arranged so that documents can be reviewed over the computer desktop.

You can set up a time for personal coaching with Dr. Barken by calling 619/886-6841. You can also send email to for details.

2 Responses to Individual Coaching With Dr. Israel Barken

  1. Richard Kasbeer (MD retired) says:

    In advocating for the AUA position, Dr. Lynch’s emphasis on his status as a prostate cancer survivor raises several relevant questions: 1.) Was his condition discovered as a result of asymptomatic screening? 2.) Precisely what treatment did he personally have? 3.) Assuming his tumor was discovered as a result of asymptomatic screening, what does he think his chances of survival to the present day would have been had he not had any screening or the resultant treatment? 4.) Beyond his obvious qualifications, what evidence does he cite to support this opinion?
    And beyond his personal case history, what scientific basis does he use to refute the logic of the USPSTF draft recommendations?:

    • Thank you for your comments. Your excellent questions will have to be addressed to Dr. Lynch, of course. I appreciate that you brought the link to the USPSTF draft document. Particularly interesting is the following sentence at the top of the document: “The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decisionmaking to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.”